Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet La... ( FRAZER Pa. Sept. 24 /- Cephalon...)

HOME >> MEDICINE >> TECHNOLOGY

Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder

Date:9/24/2009

FRAZER, Pa., Sept. 24 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced the U.S. Food and Drug Administration (FDA) has granted a priority review for its supplemental New Drug Application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV], which was filed in June of this year. The FDA decision on approval of NUVIGIL as a treatment for improving wakefulness in patients with excessive sleepiness associated with jet lag disorder due to eastbound travel is expected by December 29, 2009. There currently is no FDA-approved treatment for jet lag disorder.

The NUVIGIL sNDA is based on data from a Phase III pivotal study that evaluated the efficacy and safety of NUVIGIL (50 or 150 mg/day) in 427 healthy adults over three days during travel from the United States to Europe. These data were presented earlier this year at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies.

About NUVIGIL

NUVIGIL, the longer-lasting isomer of modafinil, was launched in the United States in June 2009 and is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work sleep disorder, also known as shift work disorder (SWD), and narcolepsy. NUVIGIL is not approved as a treatment for jet lag disorder or its associated symptoms. The NUVIGIL label includes a bolded warning for serious or life-threatening rash, including Stevens-Johnson syndrome, that has been reported in adults and children taking modafinil, a racemic mixture of S and R modafinil (the latter is armodafinil, the active ingredient in NUVIGIL). NUVIGIL is not approved for use in pediatric patients for any indication.

The most common adverse events in controlled clinical trials (five pe
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
2. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
3. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
4. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
8. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Pres. Clinton Announces Commitment From Inter-American Development Bank, Global Network for Neglected Tropical Diseases, and Pan American Health Organization to Mobilize $30 Million to Fight NTDs in the Americas at CGI Conference
11. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS

Post Your Comments:

(Date:12/16/2009)... Dec. 16 Savara, Inc., an inhalation drug ... second tranche in its Series A financing round, exceeding ... ,, Funds raised in the Series A round ... NanoCluster technology. ,, "We now have the runway ... of the NanoCluster technology," said Rob Neville, CEO of ...

(Date:12/16/2009)... Dec. 16 ChemoCentryx, Inc. today announced ... Phase 2 clinical trial of CCX354, an orally-bioavailable, ... the CCR1 chemokine receptor for the treatment of ... highly potent and selective antagonist of CCR1, a ... cells, such as monocytes and macrophages, associated with ...

(Date:12/16/2009)... -- , - ... a Total of Over,640 patients Ahead of ... NV (Euronext Brussels: THR), a biopharmaceutical company,focused ... treatments for eye,disease, vascular disease and cancer, ... of the second Phase III trial evaluating ...

[0] Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent [0] ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis [0] ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease

... is an urgent need for more,comprehensive lipid control to ... A new 30-year analysis of the,National Health and ... Association (NLA) indicates that while,Americans are doing a better ... adults with high triglycerides, a blood fat linked to ...

... Data from an investigational,open-label, randomized study assessing ... treating anemia in subjects with Stages 3 ... today at the American Society,of Nephrology 41st ... including the FDA-approved,three-times-per-week (TIW) regimen, plus once-a-week ...

Other Medicine Technology:New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity 2 New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity 3 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 2 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 3 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 4 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 5 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 6

New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting

(Date:12/16/2009)... 16 Shoppers like knowing if their ... Argentina. But grocers have found it burdensome to ... laws requiring them to provide the information at ... easyCOOLnow.com for easily making grocery and ... provisions that require retailers of unprocessed fruits, vegetables ...

(Date:12/16/2009)... 16 A new software program developed by ... healthcare facilities to calculate their staffing needs as it ... allows inpatient healthcare facilities to calculate their mandatory ... ratios and receive a daily report as to how ... a leader in risk management in the healthcare industry, ...

(Date:12/16/2009)... In a random sampling of wood pallets used ... PA, numerous pallets tested positive for Listeria and ... create health hazards for consumers. The new ... testing conducted in the Washington-Baltimore area, further illustrating ... nation,s food supply from wood pallets. ,, The ...

(Date:12/16/2009)... procedures in cardiology. The idea of publishing an ESC ... European cardiovascular imagers, is therefore long awaited. The textbook ... a patient rather than technology-based approach, helping clinicians to ... of imaging. , The book is divided into ... of cardiac imaging and its clinical use in all ...

(Date:12/16/2009)... happens when the families of sick and dying hospitalized ... for them? How do pediatricians respond to such personal ... and spirituality help some patients and families cope with ... almost always the families and patients who raise the ... the current issue of Southern Medical Journal , ...

Breaking Medicine News(10 mins):Health News:New Website Helps Grocers Comply With COOL Laws 2 Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2 Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 2 Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 3 Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 4 Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2 Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3 Health News:Prayer on the hospital floor 2

[0] New Website Helps Grocers Comply With COOL Laws [0] United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software [0] New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria [0] The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center [0] Prayer on the hospital floor

... underreport the number of hot flashes that they experience by ... to poor verbal memory, according to a study by researchers ... is published online and will appear in the September/October issue ... first study to explore the relationship between objectively measured hot ...

... especially, the brew could boost heart health, study finds , , ... lovers: Drinking up to six cups a day of caffeinated ... new study shows. , In fact, coffee might even help ... results suggest that long-term, regular coffee consumption does not increase ...

... 16 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" or the ... provider of,pharmacy benefits management services, announces that effective June ... Executive Officer (CEO),will retire from the position of CEO, ... Officer, will be appointed President and CEO.,Both will continue ...

... EDEN PRAIRIE, Minn., June 16 Through emotional ... Benatar and,Neil Giraldo helped the Starkey Hearing Foundation, ... a record $5,045,000 at its annual,"So the World ... at the,RiverCentre in Saint Paul, Minn. With money ...

... MELVILLE, N.Y., June 16 The Hain Celestial,Group, Inc. ... food and personal,care products company, today announced that Irwin ... NASDAQ Stock Market Opening Bell on,Wednesday, June 18th at ... been nearly 15 years since The Hain Celestial Group ...

... medicine in the 19th,& 20th century, Behavioral Medicine will take ... component of Behavioral Medicine, Dr. John ... Basmajian, Member of the Order of Canada, MONTREAL, ... trained Canada,s top Olympic athletes will be teaching a,workshop in ...

Other Medicine News:Health News:Hot flashes underreported and linked to forgetfulness 2 Health News:Coffee Drinkers Might Live Longer 2 Health News:Coffee Drinkers Might Live Longer 3 Health News:SXC Health Solutions announces Mark Thierer to be named President & CEO 2 Health News:Garth Brooks, Jon McLaughlin, and Pat Benatar and Neil Giraldo Raise Their Voices to Help Starkey Hearing Foundation Raise More Than $5 Million at Annual Fundraiser 2 Health News:Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM) 2 Health News:Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM) 3 Health News:Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM) 4 Health News:Biofeedback Workshops & Distance Learning Offer Credits and Training Options 2

Hot flashes underreported and linked to forgetfulness Coffee Drinkers Might Live Longer SXC Health Solutions announces Mark Thierer to be named President & CEO Garth Brooks, Jon McLaughlin, and Pat Benatar and Neil Giraldo Raise Their Voices to Help Starkey Hearing Foundation Raise More Than $5 Million at Annual Fundraiser Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM)Biofeedback Workshops & Distance Learning Offer Credits and Training Options

The Bio-Quant TROPONIN I test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of cardiac,troponin I (cTnI) in human serum specimens as an aid i...

... InstaTest IgE test kit is an immunochromatographic ... levels of immunoglobulin E in human serum ... commonly associated with allergic pathologies. It may ... some infections. Rapid detection of IgE using ...

... is an all new, completely re-engineered high performance ... LOWEST CROSSING PROFILE PTCA products available ... profile of only 0.17. Atriums all new HyperLite ... catheter ever!, ,Atriums new "Dura-Blend tip technology is ...

... The Veris physiological monitor offers a ... those specifically designed for pediatric and neonate ... up to 3T. Veris is the first ... needs of pediatric and neonate patient monitoring. ...

Medicine Products:

Troponin I - Rapid Test IgE - Rapid Test Kit HyperLite LX Veris MR Vital Signs Monitor

Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet La...( FRAZER Pa. Sept. 24 /- Cephalon...),Health